Terms: = Pancreatic cancer AND AFP, AFPD, FETA, HPAFP AND Treatment
99 results:
1. Current Roles of Ramucirumab in the Sequential treatment of Unresectable Hepatocellular Carcinoma.
Koizumi A; Komatsu S; Omiya S; Yano Y; Fujishima Y; Ishida J; Kido M; Gon H; Fukushima K; Urade T; So S; Yoshida T; Arai K; Fujinaka R; Shimura Y; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2024 May; 44(5):2055-2061. PubMed ID: 38677746
[TBL] [Abstract] [Full Text] [Related]
2. Surgical Intervention After Lenvatinib treatment in Patients With Advanced Hepatocellular Carcinoma.
Okuno M; Hatano E; Tada M; Nishimura T; Okamoto T; Sueoka H; Iida K; Nakamura I; Iijima H; Hirono S
Anticancer Res; 2024 Apr; 44(4):1727-1737. PubMed ID: 38537993
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Value of Serum α-Fetoprotein Level as an Important Characteristic of Tumor Biology for Patients Undergoing Liver Resection of Early-Stage Hepatocellular Carcinoma (BCLC Stage 0/A): A Large Multicenter Analysis.
Yao LQ; Fan ZQ; Wang MD; Diao YK; Chen TH; Zeng YY; Chen Z; Wang XM; Zhou YH; Li J; Fan XP; Liang YJ; Li C; Shen F; Lv GY; Yang T
Ann Surg Oncol; 2024 Feb; 31(2):1219-1231. PubMed ID: 37925654
[TBL] [Abstract] [Full Text] [Related]
4. [Extragonadal germ cell tumor: A case report and review of the literature].
Li P; Wu D; Xu XF; Fu D; Jia RP; Ge JP
Zhonghua Nan Ke Xue; 2022 Nov; 28(11):1026-1030. PubMed ID: 37846120
[TBL] [Abstract] [Full Text] [Related]
5. Construction and validation of a survival prognostic model for stage III hepatocellular carcinoma: a real-world, multicenter clinical study.
Hao S; Luo R; Li W; Zhao R; Qi T; Wang Z; Li N; Liu M
BMC Gastroenterol; 2023 Jun; 23(1):207. PubMed ID: 37312022
[TBL] [Abstract] [Full Text] [Related]
6. Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma.
Hu S; Liu Y; Yang Q; Chen L; Chai H; Xiao M; Qi C; Qiu W
Invest New Drugs; 2023 Jun; 41(3):532-538. PubMed ID: 37099161
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study.
Li S; Wu J; Wu J; Fu Y; Zeng Z; Li Y; Li H; Liao W; Yan M
Front Immunol; 2023; 14():1109771. PubMed ID: 36875116
[TBL] [Abstract] [Full Text] [Related]
8. Validation of quantitative prognostic prediction using ADV score for resection of hepatocellular carcinoma: A Korea-Japan collaborative study with 9200 patients.
Kang WH; Hwang S; Kaibori M; Kim JM; Kim KS; Kobayashi T; Kayashima H; Koh YS; Kubota K; Mori A; Takeda Y; Yun SS; Matsui K; Toriguchi K; Nagano H; Yoon MH; Soejima Y; Ariizumi S; Kim BS; Park Y; Yu HC; Kim BW; Lee JB; Park SJ; Jang JY; Yamaue H; Nakamura M; Yamamoto M; Endo I; ;
J Hepatobiliary Pancreat Sci; 2023 Aug; 30(8):993-1005. PubMed ID: 36808234
[TBL] [Abstract] [Full Text] [Related]
9. Outcomes of the Sequential treatment of Unresectable Hepatocellular Carcinoma Using Lenvatinib.
Nakagawa D; Komatsu S; Yano Y; Kido M; Kuramitsu K; Yamamoto A; Omiya S; Shimura Y; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2023 Feb; 43(2):911-918. PubMed ID: 36697097
[TBL] [Abstract] [Full Text] [Related]
10. Variations in dynamic tumor-associated antigen-specific T cell responses correlate with HCC recurrence after thermal ablation.
Zang C; Zhao Y; Liu G; Li K; Qin L; Zhang Y; Sun J; Wang Q; Ma L; Zhao P; Sun Y; Guo D; Yuan C; Dong T; Zhang Y
Front Immunol; 2022; 13():982578. PubMed ID: 36618423
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
Xie F; Chen B; Yang X; Wang H; Zhang G; Wang Y; Wang Y; Zhang N; Xue J; Long J; Li Y; Sun H; Xun Z; Liu K; Chen X; Song Y; Yang X; Lu Z; Mao Y; Sang X; Lu Y; Zhao H
Front Immunol; 2022; 13():1052937. PubMed ID: 36569829
[TBL] [Abstract] [Full Text] [Related]
12. Robotic versus laparoscopic major hepatectomy for hepatocellular carcinoma: short-term outcomes from a single institution.
Liu L; Wang Y; Wu T; Lin J; Deng L; Jiang J; An T
BMC Surg; 2022 Dec; 22(1):432. PubMed ID: 36528768
[TBL] [Abstract] [Full Text] [Related]
13. Rechallenge With Lenvatinib After Atezolizumab Plus Bevacizumab treatment for Hepatocellular Carcinoma.
Komatsu S; Yano Y; Kido M; Kuramitsu K; Gon H; Fukushima K; Urade T; So S; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Nov; 42(11):5479-5486. PubMed ID: 36288850
[TBL] [Abstract] [Full Text] [Related]
14. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
Kaneko S; Kurosaki M; Mashiba T; Marusawa H; Kondo M; Kojima Y; Uchida Y; Fujii H; Akahane T; Yagisawa H; Kusakabe A; Kobashi H; Abe T; Yoshida H; Ogawa C; Furuta K; Tamaki N; Tsuji K; Matsushita T; Izumi N;
J Med Virol; 2023 Jan; 95(1):e28210. PubMed ID: 36222204
[TBL] [Abstract] [Full Text] [Related]
15. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Tamaki N; Tada T; Kurosaki M; Yasui Y; Ochi H; Mashiba T; Sakamoto A; Marusawa H; Narita R; Uchida Y; Akahane T; Kondo M; Mori N; Takaki S; Tsuji K; Kobashi H; Kusakabe A; Furuta K; Arai H; Nonogi M; Ogawa C; Sato T; Tamada T; Nakamura S; Hasebe C; Tsuchiya K; Izumi N
Invest New Drugs; 2022 Dec; 40(6):1290-1297. PubMed ID: 36152108
[TBL] [Abstract] [Full Text] [Related]
16. Comparison of the long-term outcomes of patients with hepatocellular carcinoma within the Milan criteria treated by ablation, resection, or transplantation.
Zhang NN; Zheng J; Wu Y; Lv JY; Zhang SW; Zhang YM; Jiang WT; Song TQ; Kim V; Tohme S; Liu T; Zhang W; Gu J; Wang ZY; Suo YH; Wang S; Li W; Zhang L; Xie Y; Zhou YH; Liu JY; Qiu YB; Shen ZY; Hao JH; Geller D; Lu W
Cancer Med; 2023 Feb; 12(3):2312-2324. PubMed ID: 36016484
[TBL] [Abstract] [Full Text] [Related]
17. The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients.
Qian X; Liu Y; Wu F; Zhang S; Gong J; Nan Y; Hu B; Chen J; Zhao J; Chen X; Pan W; Dang S; Lu F
Viruses; 2022 Jul; 14(8):. PubMed ID: 36016291
[TBL] [Abstract] [Full Text] [Related]
18. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract] [Full Text] [Related]
19. The C-Reactive Protein to Albumin Ratio Is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: A Large Cohort Study.
Li J; Yang S; Li Y; Li C; Xia Y; Zhu S; Xia J
Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1295-1303. PubMed ID: 35835873
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.
Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Kaibori M; Iijima H; Hiasa Y; Kumada T;
Hepatol Int; 2022 Oct; 16(5):1150-1160. PubMed ID: 35749019
[TBL] [Abstract] [Full Text] [Related]
[Next]
